Type 1 Diabetes and Eating Disorder Diurnal Glucose Patterns
NCT ID: NCT01390636
Last Updated: 2015-11-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
1 participants
OBSERVATIONAL
2011-07-31
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2.1 Determine the degree of variation in glycemic profiles of individuals with an Eating Disorder and Type 1 Diabetes (ED-DMT1) and an Eating Disorder only (ED/only); and
2.2 Determine the impact of nutritional intake and planned physical activity on glucose profiles of individuals with ED-DMT1 and ED/only.
These aims will be examined by characterizing:
* glucose exposure, as measured by area under the Ambulatory Glucose Profile (AGP) median curve;
* glucose variability, as measured by the AGP inter-quartile range; and
* glucose stability, as measured by change in the AGP median curve.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ED-DMT1 and ED/only
Eating Disorder and Type 1 Diabetes and only an Eating Disorder
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with an eating disorder (Anorexia Nervosa, Bulimia Nervosa or Eating Disorder Not Otherwise Specified)
1. For ED-DMT1 group: Diagnosis of an eating disorder AND diagnosis of type 1 diabetes.
2. For ED/only group: Diagnosis of an eating disorder AND no history/diagnosis of type 1 or type 2 diabetes.
* Female.
* At least 14 years of age.
* Able to provide informed consent.
1. If the potential participant's age is at least 18 years she must be able to provide informed consent.
2. If the potential participant is less than 18 years she must have a parent or guardian able and willing to provide written informed consent on the participant's behalf. In addition, the participant must be willing to sign a consent on her own behalf.
* Participants must be able and willing to utilize the CGM system and perform required calibrations using self-monitored blood glucose.
Exclusion Criteria
* Age \< 14 years.
* History of self-injurious behavior that the senior clinician feels precludes participation.
* Unable to understand the study protocol.
* Unwilling to follow the study protocol.
* Participation in any competing research study.
* Planned ISL admission for \<4 days.
* Pregnant.
* Not able to communicate in English.
* Regular use of acetaminophen or acetaminophen containing medications and not able to modify their medication to a non-acetaminophen based medication.
14 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Park Nicollet Foundation
OTHER
Melrose Institute
UNKNOWN
International Diabetes Center at Park Nicollet
OTHER
HealthPartners Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mazze S Mazze, PhD
Role: PRINCIPAL_INVESTIGATOR
International Diabetes Center at Park Nicollet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Melrose Institute
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
04126-11-C
Identifier Type: -
Identifier Source: org_study_id